Franklin Resources Inc Nuvation Bio Inc. Transaction History

Franklin Resources Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.58 - $3.69 $229,957 - $328,893	89,131 Added 69.81%	216,814 $633,000
Q1 2024 May 13, 2024	BUY	$1.46 - $3.97 $186,417 - $506,901	127,683 New	127,683 $464,000
Q2 2023 Aug 11, 2023	SELL	$1.56 - $1.84 $29,187 - $34,426	-18,710 Reduced 92.72%	1,470 $2,000
Q1 2023 May 12, 2023	SELL	$1.6 - $2.48 $25,800 - $39,990	-16,125 Reduced 44.42%	20,180 $33,000
Q4 2022 Feb 10, 2023	BUY	$1.68 - $2.5 $60,992 - $90,762	36,305 New	36,305 $69,000
Q2 2022 Aug 11, 2022	BUY	$3.24 - $5.85 $1,739 - $3,141	537 New	537 $2,000
Q3 2021 Nov 12, 2021	SELL	$7.78 - $10.0 $6.22 Million - $8 Million	-800,000 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$9.0 - $14.57 $7.2 Million - $11.7 Million	800,000 New	800,000 $8.36 Million

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.